Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Foghorn Therapeutics

INDIANAPOLIS and CAMBRIDGE, Mass. , Dec. 13, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control ® platform.

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform

INDIANAPOLIS, Dec. 12, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL). Pirtobrutinib is an investigational, highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor.

Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting

Intuitive Surgical

Both companies look promising, but they are a bit expensive.

2 Stocks to Buy if There Is a Market Crash

The Fed decision and an Eli Lilly update are the big events on our radar next week.

Cramer's Investing Club: What we are watching next week, including the Fed and an Eli Lilly update

Eli Lilly And Co (NYSE: LLY) is making a $1.5 billion biobucks bet on Chinese biotech Regor Therapeutics to develop new therapies for metabolic disorders. Under the deal, Lilly will have a license to select Regor IP with an option to extend the license.

Eli Lilly Pens $1.5B Pact With Regor For Metabolic Disease Therapies

INDIANAPOLIS and SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. Under the terms of the agreement, Lilly will have a license to select Regor intellectual property with an option to extend the license.

Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders

INDIANAPOLIS, Dec. 9, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the CONFIDE Study (Communicating Needs and Features of IBD Experiences) that show bowel urgency – defined as the sudden or immediate need for a bowel movement – is the second most commonly reported symptom suffered by study respondents living with moderately-to-severely active ulcerative colitis (UC), regardless of whether or not they were receiving an advanced therapy (biologic or novel oral therapy). In this study, only one in four healthcare providers perceived bowel urgency as one of the top three most reported symptoms by their patients.

New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients

Eli Lilly & Company ( LLY , Financial) is a pharmaceutical giant based in the United States that specializes in the discovery, development, manufacture and sale of various pharmaceutical products. Lilly was the company that introduced Iletin, the world's first commercially available insulin medication for the treatment of diabetes, and it was also the first company to manufacture and distribute Jonas Salk's polio vaccine.

Eli Lilly's Pipeline Strength Paints a Promising Outlook

With the approval in children and infants, Lilly's (LLY) bamlanivimab with etesevimab can now be given as treatment and prevention options to high-risk individuals of any age.

Lilly (LLY) COVID-19 Antibody Gets FDA Nod for Use in Kids

The FDA has expanded the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) bamlanivimab and etesevimab administered together to include certain high-risk pediatric patients from birth to less than 12 years old. AbCellera Biologics Inc (NASDAQ: ABCL) discovered the antibody cocktail.

Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns

AbbVie

Amgen

Bristol-Myers

Gilead Sciences

Merck

Pfizer

Roche Holding AG

Roche is optimally diversified both in terms of geography and in terms of portfolio. Pfizer and Eli Lilly are also broadly diversified but are more U.S.-centric companies. AbbVie, but also Merck are currently over-reliant on a single drug but this appears to be priced into the stocks accordingly.

Diversify, Diversify - Concentration Risks Of Several Pharma Companies

Eli Lilly & Co.'s LLY, -0.93% monoclonal antibody drug has been cleared for emergency use in children under the age of 12, the Food and Drug Administration said on Friday.

The Wall Street Journal: Lilly's COVID-19 antibody drug authorized for use in children

We are adding to our holding in Eli Lilly.

Cramer's Investing Club: We are nibbling on this drug stock amid the broad market sell-off

Shares of Eli Lilly & Co. LLY, -1.68% were down 1.6% in trading on Friday after the company said the Food and Drug Administration has extended the emergency authorization for its COVID-19 antibody therapy to include children younger than 12 years old. This is the first authorization for a monoclonal antibody treatment for infants and children.

Lilly's COVID-19 antibody treatment authorized for young children and infants

INDIANAPOLIS, Dec. 3, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab administered together to include certain high-risk pediatric patients from birth to

Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12

SAN FRANCISCO, INDIANAPOLIS, and SUZHOU, China, Dec. 2, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, and Eli Lilly and Company ("Lilly") (NYSE: LLY), announce that the innovative PD-1 inhibitor sintilimab has been successfully included in the updated National Reimbursement Drug List ("NRDL") for all approved indications, according to the latest announcement from the China National Healthcare Security Administration ("NHSA"). The updated NRDL will officially take effect on January 1, 2022.

Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications

INDIANAPOLIS , Dec. 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will host a meeting for the investment community on Wednesday, Dec. 15, 2021, from 9 a.m. to 4 p.m., Eastern time.

Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting

Eli Lilly and Company (LLY) Presents at 4th Annual Evercore ISI HealthCONx Conference (Transcript)

Eli Lilly and Co. ( LLY , Financial) shareholders bore the brunt of the news that the Indianapolis-based pharma giant is drastically cutting the price of its diabetes drugs to maintain its market position in China. The announcement sent shares reeling, closing Monday at $254.81, down $5.56.

Eli Lilly Shares Slide as Price Cuts Batter Its Diabetes Business in China

Dividend boosts in the latter half of November were as expected, but with some surprises.

High Doses Of Dividend Growth Expected From Pfizer, Eli Lilly, Bristol Myers In December

We think that Eli Lilly stock (NYSE: LLY) currently is a better pick compared to Bristol Myers Squibb stock (NYSE: BMY) in the pharmaceuticals space, despite Eli Lilly being the more expensive of the two. LLY stock trades at about 9x trailing revenues, compared to 3x for BMY stock.

This Pharmaceuticals Stock Is A Better Pick Over Bristol Myers Squibb

Pharmaceutical name Eli Lilly And Co (NYSE:LLY) is breaking out in a flag pattern, with support from the 20-day moving average, as well as the +50% year-to-date level.

This Pharma Stock Looks Like a Great Pre-Holiday Buy

Lilly (LLY) reported earnings 30 days ago. What's next for the stock?

Lilly (LLY) Up 4.7% Since Last Earnings Report: Can It Continue?

The need for life-saving drugs won't subside anytime soon -- and that's what Pfizer and Eli Lilly provide.

Got $5,000? 2 Stocks to Buy and Hold Forever

Despite a mixed third-quarter earnings report last month, Eli Lilly's fundamentals appear to still be strong.

News for Eli Lilly Stock (LLY)